JO
ROIV icon

John Overdeck’s Roivant Sciences ROIV Stock Holding History

John Overdeck’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$779K Buy
+22,000
New +$650K ﹤0.01% 3811
2025
Q1 		– Sell
-12,100
Closed -$143K – 3450
2024
Q4 		$143K Sell
12,100
-111
-0.9% -$1.31K ﹤0.01% 2923
2024
Q3 		$141K Buy
12,211
+68
+0.6% +$774 ﹤0.01% 2852
2024
Q2 		$128K Sell
12,143
-29,200
-71% -$320K ﹤0.01% 2795
2024
Q1 		$436K Sell
41,343
-172,557
-81% -$1.86M ﹤0.01% 2397
2023
Q4 		$2.4M Sell
213,900
-340,564
-61% -$3.32M 0.01% 1393
2023
Q3 		$6.48M Sell
554,464
-496,772
-47% -$5.62M 0.02% 776
2023
Q2 		$10.6M Sell
1,051,236
-168,681
-14% -$1.51M 0.03% 622
2023
Q1 		$9M Buy
1,219,917
+1,194,317
+4,665% +$9.83M 0.03% 631
2022
Q4 		$205K Buy
+25,600
New +$142K ﹤0.01% 2382
2022
Q2 		– Sell
-50,158
Closed -$248K – 2874
2022
Q1 		$248K Buy
50,158
+29,794
+146% +$197K ﹤0.01% 2279
2021
Q4 		$205K Buy
+20,364
New +$169K ﹤0.01% 3921

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

John Overdeck's ROIV Position: Q2 2026 in Review

John Overdeck opened a new position in Roivant Sciences (ROIV) in Q2 2026: 22,000 shares worth $779K. The stake represents ﹤0.01% of the portfolio and ranks #3811 among its holdings. This is a return to the name: John Overdeck previously reported a position in ROIV as recently as Q4 2024.

John Overdeck first reported a position in ROIV in Q4 2021 and has held it in 12 quarters since. The position peaked at $10.6M in Q2 2023. 495 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • John Overdeck held 22,000 shares of Roivant Sciences worth $779K as of Q2 2026.
  • Roivant Sciences was a new John Overdeck position in Q2 2026.
  • Roivant Sciences made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3811 holding.
  • John Overdeck first reported a position in Roivant Sciences in Q4 2021 and has held it in 12 quarters since.
  • John Overdeck's Roivant Sciences position peaked at $10.6M in Q2 2023.
  • 495 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.